Citations

Clear

3030 citation(s) found for "Susan, M".

Sex differences in salt sensitivity to nitric oxide dependent vasodilation in healthy young adults
Eisenach, John H., Gullixson, Leah R., Kost, Susan L., Nicholson, Wayne T. , Joyner, Michael J. , Turner, Stephen T.

Mayo Clinic

Journal of Applied Physiology | December 23, 2011 | Volume: 112 | Issue: 6 | Pages: 1049-1053

10.1152/japplphysiol.01197.2011 | PMID 22194324 Get It

Dietary sodium and blood pressure regulation differs between normotensive men and women, an effect which may involve endothelial production of nitric oxide (NO). Therefore, we tested the hypothesis that differences in the NO component of endothelium-dependent vasodilation between low and high dietary sodium intake depend on sex. For 5 days prior to study, healthy adults consumed a controlled low-sodium diet (10 mmol/day, n = 30, mean age ± SE: 30 ± 1 yr, 16 men) or high-sodium diet (400 mmol/day, n = 36, age 23 ± 1 yr, 13 men). Forearm blood flow (FBF, plethysmography) responses to brachial artery administration of acetylcholine (ACh, 4 μg·100 ml tissue−1·min−1) were measured before and after endothelial NO synthase inhibition with NG-monomethyl-l-arginine (l-NMMA, 50 mg bolus + 1 mg/min infusion). The NO component of endothelium-dependent dilation was calculated as the response to ACh before and after l-NMMA accounting for changes in baseline FBF: [(FBF ACh − FBF baseline) − (FBF AChL-NMMA − FBF baselineL-NMMA)]. This value was 5.7 ± 1.3 and 2.5 ± 0.8 ml·100 ml forearm tissue−1·min−1 for the low- and high-sodium diets, respectively (main effect of sodium, P = 0.019). The sodium effect was larger for the men, with values of 7.9 ± 2.0 and 2.2 ± 1.4 for men vs. 3.1 ± 1.3 and 2.7 ± 1.0 ml·100 ml forearm tissue−1·min−1 for the women ( P = 0.034, sex-by-sodium interaction). We conclude that the NO component of endothelium-dependent vasodilation is altered by dietary sodium intake based on sex, suggesting that endothelial NO production is sensitive to dietary sodium in healthy young men but not women.
Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group
Malempati, Suman , Weigel, Brenda J. , Ingle, Ashish M., Ahern, Charlotte H., Carroll, Julie M. , Roberts, Charles T. , Schmechel, Stephen C. , Voss, Stephan D. , Cho, Steven Y., Chen, Helen X., Krailo, Mark , Adamson, Peter C. , Blaney, Susan M. , Reid, Joel M.

Mayo Clinic

Journal of Clinical Oncology | December 19, 2011 | Volume: 30 | Issue: 3 | Pages: 256-262

10.1200/jco.2011.37.4355 | PMID 22184397 Get It

Purpose A phase I/II study of cixutumumab (IMC-A12) in children with refractory solid tumors was conducted. This study was designed to assess the toxicities, pharmacokinetics, and pharmacodynamics of cixutumumab in children to determine a recommended phase II dose and to assess antitumor activity in Ewing sarcoma (ES). Patients and Methods Pediatric patients with relapsed or refractory solid tumors were treated with cixutumumab as a 1-hour intravenous infusion once per week. Two dose levels—6 and 9 mg/kg—were evaluated using a standard three-plus-three cohort design. Patients with refractory ES were treated in an expanded phase II cohort at each dose level. Results Forty-seven eligible patients with a median age of 15 years (range, 4 to 28 years) were enrolled. Twelve patients were treated in the dose-finding phase. Hematologic and nonhematologic toxicities were generally mild and infrequent. Dose-limiting toxicities included grade 4 thrombocytopenia at 6 mg/kg and grade 3 dehydration at 9 mg/kg. Mean trough concentration (± standard deviation) at 9 mg/kg was 106 ± 57 μg/mL, which exceeded the effective trough concentration of 60 μg/mL observed in xenograft models. Three patients with ES had confirmed partial responses: one of 10 at 6 mg/kg and two of 20 at 9 mg/kg. Serum insulin-like growth factor I (IGF-I) levels consistently increased after one dose of cixutumumab. Tumor IGF-I receptor expression by immunohistochemistry did not correlate with response in patients with ES. Conclusion Cixutumumab is well tolerated in children with refractory solid tumors. The recommended phase II dose is 9 mg/kg. Limited single-agent activity of cixutumumab was seen in ES.
Global TravEpiNet: A National Consortium of Clinics Providing Care to International Travelers—Analysis of Demographic Characteristics, Travel Destinations, and Pretravel Healthcare of High-Risk US International Travelers, 2009–2011
LaRocque, Regina C. , Rao, Sowmya R. , Ansdell, Vernon, Yates, Johnnie, Schwartz, Brian S. , Knouse, Mark, Cahill, John D. , Hagmann, Stefan , Vinetz, Joseph M. , Connor, Bradley A., Goad, Jeffery A. , Oladele, Alawode, Álvarez, Salvador, Stauffer, William M. , Walker, Patricia F., Kozarsky, Phyllis E., Franco‐Paredes, Carlos , Dismukes, Roberta, Rosen, Jessica , Hynes, Noreen A. , Jacquérioz, Frédérique , McLellan, Susan , Hale, DeVon C., Sofarelli, Theresa A., Schoenfeld, David , Marano, Nina , Brunette, Gary W., Jentes, Emily S. , Yanni, Emad , Sotir, Mark J., Ryan, Edward T. , Lee, Jennifer

Mayo Clinic

Clinical Infectious Diseases | December 6, 2011 | Volume: 54 | Issue: 4 | Pages: 455-462

10.1093/cid/cir839 | PMID 22144534 Get It

Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes
Hinson, Shannon R., Romero, Michael F. , Popescu, Bogdan F. Gh., Lucchinetti, Claudia F. , Fryer, James P., Wolburg, Hartwig, Fallier‐Becker, Petra, Noell, Susan , Lennon, Vanda A. , Romero, Michael F

Mayo Clinic

Proceedings of the National Academy of Sciences | December 1, 2011 | Volume: 109 | Issue: 4 | Pages: 1245-1250

10.1073/pnas.1109980108 | PMID 22128336 Get It

The astrocytic aquaporin-4 (AQP4) water channel is the target of pathogenic antibodies in a spectrum of relapsing autoimmune inflammatory central nervous system disorders of varying severity that is unified by detection of the serum biomarker neuromyelitis optica (NMO)-IgG. Neuromyelitis optica is the most severe of these disorders. The two major AQP4 isoforms, M1 and M23, have identical extracellular residues. This report identifies two novel properties of NMO-IgG as determinants of pathogenicity. First, the binding of NMO-IgG to the ectodomain of astrocytic AQP4 has isoform-specific outcomes. M1 is completely internalized, but M23 resists internalization and is aggregated into larger-order orthogonal arrays of particles that activate complement more effectively than M1 when bound by NMO-IgG. Second, NMO-IgG binding to either isoform impairs water flux directly, independently of antigen down-regulation. We identified, in nondestructive central nervous system lesions of two NMO patients, two previously unappreciated histopathological correlates supporting the clinical relevance of our in vitro findings: ( i ) reactive astrocytes with persistent foci of surface AQP4 and ( ii ) vacuolation in adjacent myelin consistent with edema. The multiple molecular outcomes identified as a consequence of NMO-IgG interaction with AQP4 plausibly account for the diverse pathological features of NMO: edema, inflammation, demyelination, and necrosis. Differences in the nature and anatomical distribution of NMO lesions, and in the clinical and imaging manifestations of disease documented in pediatric and adult patients, may be influenced by regional and maturational differences in the ratio of M1 to M23 proteins in astrocytic membranes.
A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32
Li, Dalin , Best, Timothy, Berg, David J. Van Den, Gourraud, Pierre‐Antoine , Cortessis, Victoria K. , Skol, Andrew D. , Mack, Thomas M. , Glaser, Sally L. , Weiss, Lawrence M. , Nathwani, Bharat N., Schumacher, Fredrick R. , Edlund, Christopher K., Hwang, Amie E. , Fredericksen, Zachary S., Strong, Louise C. , Link, Brian K. , Cerhan, James R. , Conti, David V. , Onel, Kenan , Cozen, Wendy , Bhatia, Ravi , Slager, Susan L. , Habermann, Thomas M. , Robison, Leslie L. , Cerhan, James R , Link, Brian K , Conti, David V

Mayo Clinic

Blood | November 16, 2011 | Volume: 119 | Issue: 2 | Pages: 469-475

10.1182/blood-2011-03-343921 | PMID 22086417 Get It

Nodular sclerosing Hodgkin lymphoma (NSHL) is a distinct, highly heritable Hodgkin lymphoma subtype. We undertook a genome-wide meta-analysis of 393 European-origin adolescent/young adult NSHL patients and 3315 controls using the Illumina Human610-Quad Beadchip and Affymetrix Genome-Wide Human SNP Array 6.0. We identified 3 single nucleotide polymorphisms (SNPs) on chromosome 6p21.32 that were significantly associated with NSHL risk: rs9268542 (P = 5.35 × 10−10), rs204999 (P = 1.44 × 10−9), and rs2858870 (P = 1.69 × 10−8). We also confirmed a previously reported association in the same region, rs6903608 (P = 3.52 × 10−10). rs204999 and rs2858870 were weakly correlated (r2 = 0.257), and the remaining pairs of SNPs were not correlated (r2 < 0.1). In an independent set of 113 NSHL cases and 214 controls, 2 SNPs were significantly associated with NSHL and a third showed a comparable odds ratio (OR). These SNPs are found on 2 haplotypes associated with NSHL risk (rs204999-rs9268528-rs9268542-rs6903608-rs2858870; AGGCT, OR = 1.7, P = 1.71 × 10−6; GAATC, OR = 0.4, P = 1.16 × 10−4). All individuals with the GAATC haplotype also carried the HLA class II DRB1*0701 allele. In a separate analysis, the DRB1*0701 allele was associated with a decreased risk of NSHL (OR = 0.5, 95% confidence interval = 0.4, 0.7). These data support the importance of the HLA class II region in NSHL etiology.
Toward semantic web based knowledge representation and extraction from electronic health records
Pathak, Jyotishman , Welch, Susan, Huff, Stanley M. , Tao, Cui , Bouamrane, Matt-Mouley , Chute, Christopher G.

Mayo Clinic

Proceedings of the first international workshop on Managing interoperability and complexity in health systems | November 16, 2011 | Volume: No volume available | Issue: No issue available | Pages: 75-78

10.1145/2064747.2064765 Get It

Improvement in Academic Behaviors After Successful Treatment of Convergence Insufficiency
Borsting, Eric , Mitchell, G. Lynn , Kulp, Marjean Taylor , Scheiman, Mitchell , Amster, Deborah, Coulter, Rachael A., Fecho, Gregory, Gallaway, Michael, Granet, David B. , Hertle, Richard W. , Rodena, Jacqueline, Yamada, Tomohiko , Group, the CITT Study, Cotter, Susan A. , Yamada, Tomohiko, Group, the CITT Study

Mayo Clinic

Optometry and Vision Science | November 11, 2011 | Volume: 89 | Issue: 1 | Pages: 12-18

10.1097/opx.0b013e318238ffc3 | PMID 22080400 Get It

ABSTRACT Purpose. To determine whether treatment of symptomatic convergence insufficiency (CI) has an effect on Academic Behavior Survey (ABS) scores. Methods. The ABS is a six‐item survey developed by the Convergence Insufficiency Treatment Trial Group that quantifies the frequency of adverse school behaviors and parental concern about school performance on an ordinal scale from 0 (never) to 4 (always) with total scores ranging from 0 to 24. The ABS was administered at baseline and after 12 weeks of treatment to the parents of 218 children aged 9 to 17 years with symptomatic CI, who were enrolled in the Convergence Insufficiency Treatment Trial and randomized into (1) home‐based pencil push‐ups; (2) home‐based computer vergence/accommodative therapy and pencil push‐ups; (3) office‐based vergence/accommodative therapy with home reinforcement; and (4) office‐based placebo therapy with home reinforcement. Participants were classified as successful (n = 42), improved (n = 60), or non‐responder (n = 116) at the completion of 12 weeks of treatment using a composite measure of the symptom score, nearpoint of convergence, and positive fusional vergence. Analysis of covariance methods were used to compare the mean change in ABS between response to treatment groups while controlling for the ABS score at baseline. Results. The mean ABS score for the entire group at baseline was 12.85 (SD = 6.3). The mean ABS score decreased (improved) in those categorized as successful, improved, and non‐responder by 4.0, 2.9, and 1.3 points, respectively. The improvement in the ABS score was significantly related to treatment outcome (p < 0.0001), with the ABS score being significantly lower (better) for children who were successful or improved after treatment as compared to children who were non‐responders (p = 0.002 and 0.043, respectively). Conclusions. A successful or improved outcome after CI treatment was associated with a reduction in the frequency of adverse academic behaviors and parental concern associated with reading and school work as reported by parents.
LIM domain only 2 protein expression,LMO2germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era
Cerhan, James R. , Morton, Lindsay M. , Maurer, Matthew J. , Asmann, Yan W. , Vasef, Mohammad A., Lynch, Charles F. , Allmer, Cristine, Lossos, Izidore S. , Rothman, Nathaniel , Hartge, Patricia, Wang, Sophia , Natkunam, Yasodha , Habermann, Thomas M. , Cozen, Wendy , Slager, Susan L. , Chanock, Stephen Jacob , Doǧan, Ahmet , Maurer, Matthew , Cerhan, James R , Morton, Lindsay M , Wang, Sophia S

Mayo Clinic

Leukemia & Lymphoma | November 9, 2011 | Volume: 53 | Issue: 6 | Pages: 1105-1112

10.3109/10428194.2011.638717 | PMID 22066713 Get It

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Metzeler, Klaus H. , Becker, Heiko , Maharry, Kati , Radmacher, Michael D., Kohlschmidt, Jessica, Mrózek, Krzysztof , Whitman, Susan P., Wu, Yue-Zhong, Schwind, Sebastian , Powell, Bayard L., Carter, Thomas H. , Wetzler, Meir , Moore, Joseph O. , Kolitz, Jonathan E. , Baer, Maria R. , Carroll, Andrew J. , Larson, Richard A. , Marcucci, Guido , Bloomfield, Clara D. , Nicolet, Deedra , Caligiuri, Michael A. , Larson, Richard A

Mayo Clinic

Blood | October 27, 2011 | Volume: 118 | Issue: 26 | Pages: 6920-6929

10.1182/blood-2011-08-368225 | PMID 22031865 Get It

Abstract The associations of mutations in the enhancer of trithorax and polycomb family gene ASXL1 with pretreatment patient characteristics, outcomes, and gene-/microRNA-expression profiles in primary cytogenetically normal acute myeloid leukemia (CN-AML) are unknown. We analyzed 423 adult patients for ASXL1 mutations, other prognostic gene mutations, and gene-/microRNA-expression profiles. ASXL1 mutations were 5 times more common in older (≥ 60 years) patients (16.2%) than those younger than 60 years (3.2%; P < .001). Among older patients, ASXL1 mutations associated with wild-type NPM1 (P < .001), absence of FLT3-internal tandem duplications (P = .002), mutated CEBPA (P = .01), and with inferior complete remission (CR) rate (P = .04), disease-free survival (DFS; P = .03), overall survival (OS; P = .006), and event-free survival (EFS; P = .002). Within the European LeukemiaNet (ELN) genetic categories of older CN-AML, ASXL1 mutations associated with inferior CR rate (P = .02), OS (P < .001), and EFS (P < .001) among ELN Favorable, but not among ELN Intermediate-I patients. Multivariable analyses confirmed associations of ASXL1 mutations with unfavorable CR rate (P = .03), DFS (P < .001), OS (P < .001), and EFS (P < .001) among ELN Favorable patients. We identified an ASXL1 mutation-associated gene-expression signature, but no microRNA-expression signature. This first study of ASXL1 mutations in primary CN-AML demonstrates that ASXL1mutated older patients, particularly within the ELN Favorable group, have unfavorable outcomes and may be candidates for experimental treatment approaches.
B7-H1 Expressed by Activated CD8 T Cells Is Essential for Their Survival
Pulko, Vesna, Harris, Kimberley J., Gibbons, Rachel, Harrington, Susan M. , Krco, Christopher J., Kwon, Eugene D., Dong, Haidong , Liu, Xin , Dong, Haidong

Mayo Clinic

The Journal of Immunology | October 25, 2011 | Volume: 187 | Issue: 11 | Pages: 5606-5614

10.4049/jimmunol.1003976 | PMID 22025548 Get It

Abstract An immunoinhibitory role of B7 homologue 1 (B7-H1) expressed by non-T cells has been established; however, the function of B7-H1 expressed by T cells is not clear. Peak expression of B7-H1 on Ag-primed CD8 T cells was observed during the contraction phase of an immune response. Unexpectedly, B7-H1 blockade at this stage reduced the numbers of effector CD8 T cells, suggesting B7-H1 blocking Ab may disturb an unknown function of B7-H1 expressed by CD8 T cells. To exclusively examine the role of B7-H1 expressed by T cells, we introduced B7-H1 deficiency into TCR transgenic (OT-1) mice. Naive B7-H1–deficient CD8 T cells proliferated normally following Ag stimulation; however, once activated, they underwent more robust contraction in vivo and more apoptosis in vitro. In addition, B7-H1–deficient CD8 T cells were more sensitive to Ca-dependent and Fas ligand-dependent killing by cytotoxic T lymphocytes. Activation-induced Bcl-xL expression was lower in activated B7-H1–deficient CD8 T cells, whereas Bcl-2 and Bim expression were comparable to the wild type. Transfer of effector B7-H1–deficient CD8 T cells failed to suppress tumor growth in vivo. Thus, upregulation of B7-H1 on primed T cells helps effector T cells survive the contraction phase and consequently generate optimal protective immunity.